FDA Advisory Panel Approves Six Peptides for Compounding Use
The Food and Drug Administration’s Pharmacy Compounding Advisory Committee voted to recommend six of seven peptide compounds for addition to the 503A Bulks List, which would allow licensed compounding pharmacies to prepare them for patients with a prescription. Approved peptides include BPC‑157 (for ulcerative colitis), MOTS‑c (for obesity and osteoporosis), KPV, TB‑500, semax and epitalon. The only compound that failed to clear the panel was emideltide, which lost by a single vote. Vote margins were narrow—reported as 8‑6 for some compounds and 7‑5 for others. The advisory panel, whose members were largely appointed by HHS Secretary Robert F. Kennedy Jr., included several doctors and pharmacists with financial ties to the peptide industry. FDA staff warned that the scientific evidence does not meet the agency’s safety and efficacy standards, and their recommendation is not binding; a final FDA decision will be issued after a public comment period. The vote reflects growing pressure from wellness influencers and “biohacking” communities to broaden access to these unproven substances.
Entities: BPC-157 · MOTS‑c · Pharmacy Compounding Advisory Committee · Robert F. Kennedy Jr. · U.S. Food and Drug Administration (FDA)
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 5 SOURCES] The panel’s recommendation is non‑binding; the FDA will issue a final decision after a public comment period.
- [● 5 SOURCES] FDA staff warned that the scientific evidence does not support approval of the peptides for safety and efficacy.
- [● 2 SOURCES] The advisory panel included members with financial ties to the peptide industry, appointed by HHS Secretary Robert F. Kennedy Jr.
- [● 3 SOURCES] Emideltide was the only peptide rejected, losing by a single vote.
- [● 4 SOURCES] The FDA Pharmacy Compounding Advisory Committee voted to recommend adding BPC‑157 to the 503A Bulks List for compounding. (recommended for ulcerative colitis)
- [● 3 SOURCES] Voting margins were narrow, reported as 8‑6 for some compounds and 7‑5 for others.
- [● 4 SOURCES] The vote reflects growing pressure from wellness influencers and 'biohacking' communities to broaden access to unproven peptide substances.
- [● 5 SOURCES] Six of seven peptide compounds were approved for addition to the 503A Bulks List.